BRPI0900896B8 - cepa de bcg pasteur auxotrófico recombinante - Google Patents
cepa de bcg pasteur auxotrófico recombinanteInfo
- Publication number
- BRPI0900896B8 BRPI0900896B8 BRPI0900896A BRPI0900896A BRPI0900896B8 BR PI0900896 B8 BRPI0900896 B8 BR PI0900896B8 BR PI0900896 A BRPI0900896 A BR PI0900896A BR PI0900896 A BRPI0900896 A BR PI0900896A BR PI0900896 B8 BRPI0900896 B8 BR PI0900896B8
- Authority
- BR
- Brazil
- Prior art keywords
- delta
- strain
- recombinant
- pasteur
- hsp60
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 abstract 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 244000045947 parasite Species 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 abstract 1
- 241000242680 Schistosoma mansoni Species 0.000 abstract 1
- 101000878031 Schistosoma mansoni 14 kDa fatty acid-binding protein Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/43559—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from trematodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
cepa de bcg pasteur auxotrófico recombinante e seu uso no controle de infecções humanas causadas por parasitas. a presente invenção se refere a uma cepa vacinal de mycobacterium bovis bcg recombinante expressando o antígeno sm14 de schistosoma mansoni (bcgr pasteur (delta)leud/p(delta)k410-hsp60*-sm14). a cepa vacinal da presente invenção é empregada para o controle de infecções causadas por parasitas, especialmente schistosoma mansoni. a cepa vacinal é uma cepa auxotrófica para o aminoácido leucina derivada da subcepa bcg pasteur complementada para leucina após transformação genética com a construção p(delta)k410-hsp60*-sm14. a eficácia da cepa bcgr pasteur (delta)leud/p(delta)k410-hsp60*-sm14 para o controle da infecção com schistosorna mansoni com base na expressão do antígeno sm14 recombinante in vivo é demonstrada na presente invenção.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0900896A BRPI0900896B8 (pt) | 2009-03-11 | 2009-03-11 | cepa de bcg pasteur auxotrófico recombinante |
| JP2011553235A JP2012519496A (ja) | 2009-03-11 | 2010-03-10 | 組換え型栄養要求性ｂｃｇパスツール株及び、寄生虫によって引き起こされるヒトの感染症を制御するための同株の使用 |
| EP10750256.9A EP2407545B1 (en) | 2009-03-11 | 2010-03-10 | Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites |
| PCT/BR2010/000065 WO2010102363A1 (pt) | 2009-03-11 | 2010-03-10 | Cepa de bcg pasteur auxotrófico recombinante e seu uso no controle de infecções humanas causadas por parasitas |
| US13/255,734 US20120093774A1 (en) | 2009-03-11 | 2010-03-10 | Auxotrophic recombinant bcg strain pasteur and use thereof in the control of human infections caused by parasites |
| CN2010800204174A CN102439155A (zh) | 2009-03-11 | 2010-03-10 | 营养缺陷型重组体巴斯德bcg菌株及其在抗寄生虫导致的人体感染中的应用 |
| AU2010223786A AU2010223786B2 (en) | 2009-03-11 | 2010-03-10 | Auxotrophic, recombinant BCG strain Pasteur and use thereof for combating human infections caused by parasites |
| AP2011005916A AP3794A (en) | 2009-03-11 | 2010-03-10 | Auxotrophic recombinant BCG strain pasteur and usethereof in the control of human infections caused by parasites. |
| NZ595662A NZ595662A (en) | 2009-03-11 | 2010-03-10 | Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites |
| ES10750256.9T ES2595372T3 (es) | 2009-03-11 | 2010-03-10 | Cepa Pasteur de BCG auxótrofa y recombinante y su uso para combatir infecciones humanas causadas por parásitos |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0900896A BRPI0900896B8 (pt) | 2009-03-11 | 2009-03-11 | cepa de bcg pasteur auxotrófico recombinante |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0900896A2 BRPI0900896A2 (pt) | 2010-11-16 |
| BRPI0900896B1 BRPI0900896B1 (pt) | 2020-12-08 |
| BRPI0900896B8 true BRPI0900896B8 (pt) | 2021-05-25 |
Family
ID=42727722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0900896A BRPI0900896B8 (pt) | 2009-03-11 | 2009-03-11 | cepa de bcg pasteur auxotrófico recombinante |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120093774A1 (pt) |
| EP (1) | EP2407545B1 (pt) |
| JP (1) | JP2012519496A (pt) |
| CN (1) | CN102439155A (pt) |
| AP (1) | AP3794A (pt) |
| AU (1) | AU2010223786B2 (pt) |
| BR (1) | BRPI0900896B8 (pt) |
| ES (1) | ES2595372T3 (pt) |
| NZ (1) | NZ595662A (pt) |
| WO (1) | WO2010102363A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103203028A (zh) * | 2012-12-03 | 2013-07-17 | 西南大学 | 一种提高抗肝片吸虫病dna疫苗免疫保护率的疫苗组合及制备方法 |
| BR102018003245A2 (pt) * | 2018-02-20 | 2019-09-10 | Fundação Oswaldo Cruz | oligonucleotídeo, conjunto de oligonucleotídeos, método para detecção simultânea de neisseria meningitidis, streptococcus pneumoniae e haemophilus influenzae, e, kit. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0303266B8 (pt) * | 2003-01-31 | 2021-05-25 | Fundacao Oswaldo Cruz | proteína recombinante sm14, composição imunogênica, e,kit de diagnóstico. |
-
2009
- 2009-03-11 BR BRPI0900896A patent/BRPI0900896B8/pt active IP Right Grant
-
2010
- 2010-03-10 ES ES10750256.9T patent/ES2595372T3/es active Active
- 2010-03-10 EP EP10750256.9A patent/EP2407545B1/en active Active
- 2010-03-10 JP JP2011553235A patent/JP2012519496A/ja active Pending
- 2010-03-10 US US13/255,734 patent/US20120093774A1/en not_active Abandoned
- 2010-03-10 NZ NZ595662A patent/NZ595662A/xx unknown
- 2010-03-10 CN CN2010800204174A patent/CN102439155A/zh active Pending
- 2010-03-10 WO PCT/BR2010/000065 patent/WO2010102363A1/pt not_active Ceased
- 2010-03-10 AP AP2011005916A patent/AP3794A/en active
- 2010-03-10 AU AU2010223786A patent/AU2010223786B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0900896A2 (pt) | 2010-11-16 |
| EP2407545A4 (en) | 2013-06-19 |
| BRPI0900896B1 (pt) | 2020-12-08 |
| NZ595662A (en) | 2013-09-27 |
| ES2595372T3 (es) | 2016-12-29 |
| AU2010223786B2 (en) | 2016-07-14 |
| AP3794A (en) | 2016-08-31 |
| WO2010102363A1 (pt) | 2010-09-16 |
| AP2011005916A0 (en) | 2011-10-31 |
| JP2012519496A (ja) | 2012-08-30 |
| CN102439155A (zh) | 2012-05-02 |
| EP2407545B1 (en) | 2016-07-06 |
| WO2010102363A8 (pt) | 2011-10-06 |
| EP2407545A1 (en) | 2012-01-18 |
| AU2010223786A1 (en) | 2011-11-03 |
| US20120093774A1 (en) | 2012-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089797A1 (es) | Vacunas contra clostridum difficile que comprenden toxinas recombinantes | |
| MX2011008791A (es) | Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. | |
| DK2566507T3 (da) | Biokonjugatvacciner med kapselformige grampositive bakterier | |
| BR112014020019A2 (pt) | vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes | |
| WO2010019262A3 (en) | Polyvalent vaccine | |
| BRPI0923448A2 (pt) | vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina. | |
| AR076941A1 (es) | Cepa de bacillus para una mayor produccion de proteina | |
| ES2663872T3 (es) | Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria | |
| AR083162A1 (es) | Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos | |
| MX2011011186A (es) | Una vacuna antituberculosis tb para evitar la reactivacion. | |
| PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
| BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
| BR112012005349A2 (pt) | composição imunogênica, seu método de fabricação, método de fabricação de uma composição de vacina de matriz de proteína, e uso | |
| WO2014009586A8 (es) | Vectores para la transformacion de mycoplasma hyopneumoniae, cepas transformadas de m. hyopneumoniae, y uso correspondiente | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| MD20120127A2 (en) | Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV | |
| AU2012277893A8 (en) | Canine coronavirus vaccine | |
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| PH12021552477A1 (en) | Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof | |
| WO2012036391A3 (ko) | 돼지 써코바이러스２(ｐｃｖ２) 유전자의 표면발현용 벡터 및 이로 형질전환된 살모넬라 백신 균주 | |
| BRPI0900896B8 (pt) | cepa de bcg pasteur auxotrófico recombinante | |
| WO2012078051A3 (en) | IPN Vaccine | |
| CO6700818A2 (es) | Vectores de parapoxvirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B15V | Prolongation of time limit allowed |